Skip to content

Tuberculosis


Tuberculosis (TB) is a serious infectious disease caused by bacteria.  It is preventable and curable.

  • Get the basics about TB from the CDC here  

The goal of the Alaska Tuberculosis (TB) Program is the eventual elimination of TB from Alaska.

TB AK infographic64percent.pngTBiceberggraphic80percent.png
 

The Alaska TB Program:

  • provides medications for persons with active TB disease
  • helps to ensure that all persons with TB infection or disease are on appropriate regimens
  • assists with the monitoring and case management of persons on therapy for TB infection or disease
  • assists with the identification of persons exposed to TB
  • provides consultations to providers, public health nurses, and the public
  • provides TB education and outreach to partners throughout the state
Contact us:  (907) 269-8000 or tb@alaska.gov


Provider Toolkit

 
​*Suspected or confirmed active tuberculosis disease is a reportable condition in Alaska.*  
Cases should be reported to the Alaska TB Program within 2 business days.  Please call the Section of Epidemiology at 907-269-8000, or complete the appropriate report form and fax to 907-561-4239.

 
Screening/Assessment 

The USPSTF recom​mends screening for latent TB infection (LTBI) in populations at increased risk.  Finding and treating patients with LTBI is key to controlling the TB epidemic.

Testing/Diagnosis
IGRA (blood) testing is now approved for all persons>2 years of age and has some advantages over TST (skin test), especially in foreign-born persons who may have received BCG vaccination in the past.
There are now shorter-course regimens which make LTBI treatment easier.  It is very important to rule out active TB disease prior to starting treatment for LTBI.

The TB Manual is in the process of being updated--thank you for your patience.


Other Forms

Alaska School Screening  *Update for 2019-2020 School Year*
​​Video DOT (Directly Observed Therapy)

Spotlight



 
NEW: Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection (6/29/18).  

 
The updated recommendations, published in CDC’s Morbidity and Mortality Weekly Report (MMWR) support and expand the use of an effective, yet shorter treatment regimen to reach even more people with latent TB infection.

 

 Public Service Announcement: World TB Day - March 24

 


​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​